Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 1/2007

01-01-2007 | Original Paper

Expression of IGFBP2 in Gastric Carcinoma and Relationship With Clinicopathologic Parameters and Cell Proliferation

Authors: Lihua Zhang, Wenbin Huang, Jieyu Chen, Xiaojun Zhou, Zhenfeng Lu, Hangbo Zhou

Published in: Digestive Diseases and Sciences | Issue 1/2007

Login to get access

Abstract

The insulin-like growth factor (IGF) axis is a complex system composed of two mitogenic ligands, IGF-I and IGF-II, two receptors, IGF-IR and IGF-IIR, and six binding proteins, IGFBP1 to IGFBP6. The IGFBPs exert their actions through their regulation of IGF bioavailability for IGF receptors. The present study evaluated the correlation between IGFBP2 expression and clinicopathologic parameters and cell proloferation in cancer by using surgically resected tissue specimens from 97 patients with gastric carcinoma treated at our hospital. Immunohistochemical staining was performed using IGFBP2 and Ki-67 monoclonal antibody. An obvious difference existed in the IGFBP2 expression between carcinomas and normal mucosa. Correlation between IGFBP2 expression and the depth of penetration, lymph node metastasis, and clinical stage were observed. There was positive correlation between IGFBP2 expression and Ki-67 expression. We conclude that IGFBP2 may be involved in carcinogenesis and progression of gastric carcinoma by promoting cell proliferation.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P (2000) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156CrossRef
2.
Konturek PC, Konturek SJ, Sulekova Z, Meixner H, Bielanski W, Starzynska T, Karczewska E, Marlicz K, Stachura J, Hahn EG (2001) Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer. Aliment Pharmacol Ther 15:989–999PubMedCrossRef
3.
Han SU, Lee JH, Kim WH, Cho YK, Kim MW (1999) Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg 23:1176–1180PubMedCrossRef
4.
Rosenfeld RG, Roberts CT (eds) (1999) The IGF System. Totowa, NJ: Humana Press Inc.
5.
LeRoith D (1996) Insulin-like growth factor receptors and binding proteins. Baillieres Clin Endocrinol Metab 10:49–73PubMedCrossRef
6.
Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801–831PubMedCrossRef
7.
Wetterau LA, Moore MG, Lee KW, Shim ML, Cohen P (1999) Novel aspects of the insulin-like growth factor binding proteins. Molecular Genetics Metab 68:161–181CrossRef
8.
Hoeflich A, Lahm H, Blum W, Kolb H, Wolf E (1998) Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Lett 434:329–334CrossRef
9.
Hoeflich A, Nedbal S, Blum WF, Erhard M, Lahm H, Brem G, Kolb HJ, Wanke R, Wolf E (2001) Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2. Endocrinology 142:1889–1898PubMedCrossRef
10.
Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS (1997) Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 82:2308–2313PubMedCrossRef
11.
El Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G (1994) Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor binding proteins in patients with colorectal cancer. Int J Cancer 57:491–497PubMedCrossRef
12.
Ho PJ, Baxter RC (1997) Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol 46:333–342CrossRef
13.
Muller HL, Oh Y, Lehrnbecher T, Blum WF, Rosenfeld RG (1994) Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 79:428–434PubMedCrossRef
14.
Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW (2004) Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 32:859–868PubMedCrossRef
15.
Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P (2003) Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 105:14–19PubMedCrossRef
16.
Yi HK, Hwang PH, Yang DH, Kang CW, Lee DY (2001) Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins(IGFBPs) in human gastric cancer cells. Eur J Cancer 37:2257PubMedCrossRef
17.
He T, Wu XT, Yang ZM, Da MX, Zhang MM, Qian K (2005) IGFBP-2 mRNA expression in gastric cancer tissues and its roles in proliferation, differentiation and peritoneal metastasis of gastric cancer. SiChuan Da Xue Xue Bao Yi Xue Ban 36:187–189PubMed
18.
Pinto-de-Sousa J, David L, Seixas M, Pimenta A (2001) Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum. Dig Surg 18:102–110PubMedCrossRef
19.
Sobin LE, Whitekind CH (eds) (2001) TNM classification of malignant tumours. International Union Against Cancer, 5th ed. New York: John Wiley & Sons
20.
Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG (1993) Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76:1031–1035PubMedCrossRef
21.
Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A (1993) Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77:229–233PubMedCrossRef
22.
Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y (1998) Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 83:1713–1720PubMedCrossRef
23.
Wex H, Vorwerk P, Mohnike K, Bretschneider D, Kluba U, Aumann V, Blum WF, Mittler U (1998) Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone. Br J Cancer 78:515–520PubMed
24.
Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, Busch C, Stalsberg H (2005) Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 58:361–366PubMedCrossRef
25.
Richardsen E, Ukkonen T, Bjnren T, Mortensen E, Egevad L, Busch C (2003) Overexpression of IGFBP2 is a marker for malignant transformation in prostate epithelium. Virchows Arch 442:329–335PubMed
26.
Song SW, Fuller GN, Khan A, Kong S, Shen W, Taylor E, Ramdas L, Lanf FF, Zhang W (2003) IIp45, an insulin-like growth factor binding protein 2 (IGFBP2) binding protein, antagonizes IGFBP2 stimulation of glioma cell invasion. PNAS 100:13970–13975PubMedCrossRef
27.
Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi OP (1999) Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst (Bethesda) 91:1758–1764CrossRef
28.
Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK, Zhang W (1999) Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 59:4228–4232PubMed
29.
Sato T, Yoshinaga K, Okabe S, Okawa T, Higuchi T, Enomoto M, Takizawa T, Sugihara K (2003) Cyclooxygenase-2 expression and its relationship with proliferation of colorectal adenomas. Jpn J Clin Oncol 33:631–635PubMedCrossRef
Metadata
Title
Expression of IGFBP2 in Gastric Carcinoma and Relationship With Clinicopathologic Parameters and Cell Proliferation
Authors
Lihua Zhang
Wenbin Huang
Jieyu Chen
Xiaojun Zhou
Zhenfeng Lu
Hangbo Zhou
Publication date
01-01-2007
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9358-z

Other articles of this Issue 1/2007

Digestive Diseases and Sciences 1/2007 Go to the issue

Original Paper

Does Adding Misoprostol to Standard Intravenous Proton Pump Inhibitor Protocol Improve the Outcome of Aspirin/NSAID-Induced Upper Gastrointestinal Bleeding?

Original Paper

Cyclooxygenase-2 Expression in Hepatocellular Carcinoma, Cirrhosis and Chronic Hepatitis in the United States

Original Paper

Effect of Rebamipide on the Colonic Barrier in Interleukin-10-Deficient Mice

Original Article

Exacerbation of Sickle Cell Disease Itself as a Cause of Abnormal Liver Chemistry Tests

Letter to the Editor

Successful Treatment of Refractory Duodenal Crohn’s Disease with Infliximab

Original Paper

Anti-Saccharomyces cerevisiae Antibody Does Not Differentiate Between Crohn's Disease and Intestinal Tuberculosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits